KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Current Deferred Revenue (2016)

Gilead Sciences' Current Deferred Revenue history spans 8 years, with the latest figure at $202.0 million for Q4 2016.

  • For Q4 2016, Current Deferred Revenue fell 54.09% year-over-year to $202.0 million; the TTM value through Dec 2016 reached $202.0 million, down 54.09%, while the annual FY2016 figure was $202.0 million, 54.09% down from the prior year.
  • Current Deferred Revenue reached $202.0 million in Q4 2016 per GILD's latest filing, down from $361.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $529.0 million in Q1 2016 to a low of $93.7 million in Q2 2012.
  • Average Current Deferred Revenue over 5 years is $214.2 million, with a median of $126.8 million recorded in 2013.
  • Peak YoY movement for Current Deferred Revenue: soared 296.72% in 2015, then plummeted 54.09% in 2016.
  • A 5-year view of Current Deferred Revenue shows it stood at $103.2 million in 2012, then rose by 7.6% to $111.0 million in 2013, then grew by 20.72% to $134.0 million in 2014, then skyrocketed by 228.36% to $440.0 million in 2015, then tumbled by 54.09% to $202.0 million in 2016.
  • Per Business Quant, the three most recent readings for GILD's Current Deferred Revenue are $202.0 million (Q4 2016), $361.0 million (Q3 2016), and $345.0 million (Q2 2016).